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Introduction
Unrelated cord blood transplantation (UCBT) is an alterna-
tive option for patients without a suitable HLA matched
donor.1 Tolerance of some degree of HLA mismatch, with rel-
atively low rates of both acute and chronic graft-versus-host
disease (GvHD) makes UCBT an interesting source of
hematopoietic stem cells for both pediatric and adult trans-
plants.
Different studies comparing UCBT to matched unrelated
donor transplant2-4 showed no significant difference in disease
free survival in children and adults; however, probability of
neutrophil and platelet engraftment is lower and delayed after
UCBT. Many approaches are currently available that aim to
improve engraftment after UCBT, such as the use of double
UCBT (dUCBT) and reduced intensity conditioning regimen
(RIC).5 However, the hematopoietic engraftment remains
lower after double UCBT when compared to other stem cell
sources.6
Other strategies7,8 are under investigation to prevent graft fail-
ure (GF) by the intrabone infusion of UCB and the co-infusion
of expanded single UCB unit.9 Nevertheless, delayed engraft-
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Graft failure is a major complication after unrelated cord blood transplantation. Presence of HLA-antibodies before
cord blood transplantation may impact graft failure. To analyze the effect of anti-HLA antibodies on unrelated cord
blood transplantation outcomes, we analyzed 294 unrelated cord blood transplant recipients after reduced inten-
sity conditioning regimen. The majority of the patients (82%) were transplanted for malignancies, 60% with dou-
ble-unrelated cord blood transplant, 63% were HLA mismatched. Retrospectively, pre-unrelated cord blood trans-
plant serum was tested for HLA-Ab using LuminexTM platform. Results were interpreted as mean fluorescence
intensity (MFI) against donor-specific mismatch. Among 62 recipients (23%) who had anti-HLA antibodies before
unrelated cord blood transplant, 14 patients had donor specific anti-HLA antibodies (DSA) (7 were donor-specific
anti-HLA antibodies for single unrelated cord blood transplant and 7 for double unrelated cord blood transplant).
Donor specific anti-HLA antibodies threshold ranged from 1620-17629 of mean fluorescence intensity (MFI).
Cumulative incidence of Day-60 neutrophil engraftment was 76%: 44% for recipients with donor specific anti-
HLA antibodies and 81% in those without donor specific anti-HLA antibodies (P=0.006). The cumulative inci-
dence of 1-year transplant related mortality was 46% in patients with donor specific anti-HLA antibodies and 32%
in those without antibodies (P=0.06). The presence of donor specific anti-HLA antibodies was associated with a
trend for decreased survival rate (42% vs. 29%; P=0.07).  Donor specific anti-HLA antibody in recipients of unre-
lated cord blood transplant is associated with graft failure and decreased survival. Patient’s screening for donor spe-
cific anti-HLA antibodies before unrelated cord blood transplantation is recommended before choosing an HLA
mismatched cord blood unit. Whenever possible it is important to avoid selecting a unit for which the patient has
donor specific anti-HLA antibodies. 
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ment and GF continue to be a major concern after UCBT.
Importantly, the detection of patient-, donor-, disease-
and transplant-related factors that are associated with
engraftment may help clinicians to choose the best UCB
unit and to improve the techniques of transplantation.
Since most UCBT are performed with HLA mismatched
CB units,10 the presence of anti-HLA (donor specific anti-
bodies, DSA) in the patients against the UCB unit can be
an issue for engraftment. Anti-HLA antibodies before
transplant may occur due to the alloimunization to HLA
through blood transfusions, pregnancy and also in some
unexposed individuals.11-14 In unrelated donor recipients,
Spellman et al. reported pre-transplant anti-HLA antibod-
ies associated to GF and higher mortality. Interestingly, in
this case control study, higher frequency of DSA anti HLA
DP was reported.13
In the UCBT setting, few studies with controversial
results are available on the impact of DSA and outcomes.
Two series reporting respectively 38615 and 73 patients15
receiving single or double UCBT showed an increased risk
of GF and lower survival for patients with positive DSA.
However, another report showed no association between
the presence of DSA and transplant outcomes in 126
dUCBT recipients.16
In order to address the impact of the anti-HLA antibod-
ies on outcomes after UCBT, in an independent dataset
and using standardized methodologies for detection of
DSA, we performed a retrospective registry-based analy-
sis including only patients given an RIC UCBT in 16
French transplant centers, from 2000 to 2011.
Design and Methods
Patients 
Using the Eurocord database, we selected 415 UCBT recipients
(n=360 first transplant) after RIC regimen. Immunology laborato-
ries of French transplant centers were requested to perform stan-
dardized tests for the detection of DSA retrospectively when sam-
ples were available and if not yet tested. Therefore, 294 patients
were assessed for anti-HLA antibodies screening before UCBT
and were included in this analysis. All patients received a single
(sUCBT) or double unmanipulated UCB unit as their first graft
after an RIC. RIC was defined as a conditioning regimen not con-
taining either total body irradiation (TBI) with a dose equal or
superior to 6 Gy, or a dose of oral busulfan equal or superior to 8
mg/kg when administered orally, or to 6.4 mg/kg intravenously. 
Data on patients’ and graft characteristics, as well as on out-
comes, were collected using the Eurocord standard forms (100-day
and yearly follow-up forms). The Institutional Review Boards of
the Eurocord-Netcord scientific committee approved this study.
According to EBMT rules, patients provided informed consent
allowing for data submission to EBMT and Eurocord database and
use of data for research in accordance with the Declaration of
Helsinki.
Antibody testing 
Pre-transplant patients’ sera samples cryopreserved in each par-
ticipating center were tested retrospectively, unless previously
analyzed before the transplantation. The patient serum was col-
lected and tested or stored (for later testing) within a maximum of
30 days before UCBT, according to transplant center protocol for
patients and donor selection.
HLA antibodies screening was performed either by an Elisa
method (Lambda Antigen TrayTM Mixed Class I & II -One Lambda
Inc., Canoga Park, CA, USA or Dynaship-Dynal) or by a Luminex
assay (LABScreen Mixed class I and II, One Lambda Inc., Canoga
Park, CA, USA or Lifecodes Lifescreen Deluxe-Gen-Probe Inc., San
Diego, CA, USA). In our series, 85% of the antibody identification
was performed with the Luminex from One Lambda Inc. All lab-
oratories participating in this study were accredited by the EFI
(European Federation for Immunogenetics). Laboratories per-
formed the Luminex typing according to the manufacturer’s rec-
ommendations and the laboratory guidelines.
All samples with a positive screening were further evaluated
using the Luminex-based single antigen flow beads to determine
HLA specificities (LABScreen Single Antigen class I and II, One
Lambda Inc., Canoga Park, CA, USA or Lifecodes LSA class I or
class II -Gen-Probe Inc., San Diego, CA, USA). Samples were con-
sidered positive for specific HLA antigens based on a background
adjusted for mean fluorescence intensity (MFI) greater than 1000.
All the DSA+ cases but one were identified using the OneLambda
Luminex single antigen technique.
Definitions and end points
A patient was considered anti-HLA antibody negative when the
initial screening test was negative. Each patient with a positive
screening for anti-HLA antibodies was further investigated for
donor specific anti-HLA antibodies (DSA) with a Luminex Single
Antigen assay. Patients with anti-HLA antibodies directed against
an antigen present in the UCB infused, or in at least one of the
UCB infused in the case of double cord transplantation were
defined as DSA positive cases.
Neutrophil engraftment was defined as achieving absolute neu-
trophil count (ANC) of 0.5×109/L or over for three consecutive
days, and platelet recovery was defined as achieving platelet count
of 20×109/L or over unsupported by platelet transfusions for seven
days. Primary graft failure was defined as never having achieved
ANC of 0.5×109/L or over lasting for at least three consecutive
days or ANC of 0.5x109/L or over without donor engraftment
(autologous recovery).  Secondary graft failure was defined as hav-
ing achieved ANC of 0.5×109/L or over with subsequent decline or
loss of donor engraftment. Full donor chimerism was defined as
95% or over leukocytes of donor origin in peripheral blood or mar-
row samples, measured by different techniques according to each
transplant center’s protocol. Autologous reconstitution was
defined as 95% or over leukocytes of recipient origin. Mixed
chimerism was defined by the presence of more than 5% but less
than 95% leukocytes of donor origin. The diagnosis and grading
of acute and chronic GvHD was assigned by the transplant center
using standard criteria.17 Transplant-related mortality (TRM) was
defined as the time from transplantation to death not related to
disease recurrence or progression. Overall survival (OS) was calcu-
lated from the date of UCBT until death or last observation alive. 
Statistical analysis 
Median values and ranges were used for continuous variables
and percentages for categorical variables (Table 1). For each contin-
uous variable, the study population was initially split into quartiles
and in two groups by the median. The probabilities of OS and LFS
were calculated using the Kaplan-Meier method and the log rank
test for univariate comparisons.18 The probabilities of neutrophil
engraftment, grade II-IV acute and chronic GvHD, relapse and
NRM were calculated with the cumulative incidence (CI) estima-
tor.  Multivariate analyses were performed using Fine and Gray’s
proportional hazards regression model.19 Variables that reached a
P value of 0.15 in the univariate analysis were included in the ini-
tial models, and variables were eliminated one at a time in a step-
wise fashion in order to only keep variables that reached a P value
of 0.05 or less in the final model. P values were two-sided.
Anti-HLA before UCBT 
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Statistical analyses were performed with SPSS (SPSS Inc., Chicago,
IL, USA) and Splus (MathSoft Inc., Seattle, WA, USA).
Results
Patients’ characteristics
Baseline patients’ and transplant characteristics are
shown in Table 1. In summary, 39% were transplanted for
acute leukemia, 37% were transplanted with a single
UCBT and 63% a double UCBT. Most of the patients
received UCB units with 4/6 HLA disparity (antigen level
for HLA-A and B, allelic level for DRB1). 
All patients received an RIC regimen. Median infused
total nucleated cell dose (TNC) was 3.6×107/kg (range 1-
17×107/kg) and median CD34+ cell dose was 1.6×105/kg
(range 1-10×105/kg).
Anti-HLA antibodies
Of the 294 cases tested 62 (21%) were anti-HLA anti-
body positive.
Of the positive cases, 14 were positive against the UCB
(DSA+). Among the 14 DSA+, 8 had antibodies against
HLA class I antigens, 3 had antibodies against HLA class II
and 3 against class I and II. The groups of patients with
and without DSA were similar in respect to recipients’ age
at UCBT, proportion of gender disparity between donor
and recipients, type of diagnosis and in graft composition
(Table 1). All the 14 patients with DSA received a mini-
mum TNC dose of 2.5×107/Kg at infusion.
Specificity of the patients transplanted with DSA and
their outcomes are shown in Table 2. 
DSA and engraftment 
CI of Day-60 neutrophil engraftment was 78±1%, and
the median time to engraftment was 20 (range 13-60)
days. Seventy-three patients experienced graft failure. No
significant difference was found in the CI of engraftment
for patients with HLA-Ab not specific to antigens present
in the UCB units (n=48) when compared with the anti-
body negative group. 
CI engraftment was 79% in case of absence of antibody
(n=232), and was 81% for no-DSA group (n=48) (P=0.28).
The CI of engraftment was 77% for DSA negative and
44% for DSA positive patients (P=0.003) (Figure 1). Three
out of the 8 patients with DSA directed to class I antigen
A. Ruggeri et al.
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Table 1. Patients’ and transplant characteristics.
All patients, n=294 DSA+, n=14 DSA-, n=280 P
N. % N. % N. %
Age, years 0.48
Median age (range) 40 (1-67) 42 (5-62) 39 (1-67)
Gender 0.7
Male 158 53 7 50 151 54
Female 136 46 7 50 129 46
Disease 0.18
AL 115 42 5 36 110 38
MDS/CML 48 16 3 21 45 16
Lymphoma/PCD 80 25 2 14 78 28
BMF 43 14 4 28 39 15
Immune deficiency 8 3 0 8 3
Type of graft 0.30
Single UCBT 109 37 7 50 102 37
Double UCBT 185 63 7 50 178 63
HLA match*: 0.35
0-1 mismatch 85 29 3 21 83 29
2 mismatches 204 71 11 79 195 71
Missing data 2 / 2 /
Median TNC 3.6 (1-17) 3.7 (2.5-5) 3.6 (1-17) 0.5
at infusion x107/Kg 
(range)
Median CD34+ cell 1.3 (1-10) 1.4 (1-4) 1.3 (1-10) 0.6
at infusion x105/Kg  
(range)
Conditioning regimen
CyFluTBI2Gy 199 76 8 66 191 76 0.36
ATG before Day 0 83 35 5 36 78 34 0.8
GvHD prophylaxis 0.7
CsA+ MMF+Pred 217 80 8 66 209 82
Missing data 24 / 2 22 /
AL: acute leukemia; MDS: myelodysplastic syndrome; CML: chronic myelogenous leukemia; PCD: plasma cell disorders; BMF: bone marrow failure syndrome;  UCBT: unrelated cord
blood transplantation; HLA: human leukocyte antigen;  *HLA match: antigen level for class I, allelic level for class II; TNC: total nucleated cell dose; Cy: cyclophosphamide; Flu: flu-
darabine; TBI: total body irradiation; ATG: anti thymocyte globulin; GvHD: graft versus host disease; CsA: cyclosporin A; MMF: mycophenolate mofetil;  Pred: prednisone.
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engrafted, and 2 out of the 3 with DSA against class II anti-
gen, and one out of the 3 against both class I and class II
antigens engrafted as well.
Univariate analysis showed the presence of DSA associ-
ated with engraftment (P=0.003). The other factors associ-
ated with lower myeloid engraftment were patients trans-
planted before 2008 (67% vs. 80%; P=0.003) and non-
malignant disease (64% vs. 76%; P=0.005). Prognostic fac-
tors tested in univariate analysis were donor/recipient
gender mismatch, recipient age, prior autologous trans-
plant, type of graft (single or double UCBT), TNC doses at
collection and infusion, number of HLA disparities, use of
ATG before Day 0 and presence of anti-HLA Ab non-
donor-specific. In multivariate analysis, the only factor
independently associated with neutrophil recovery was
the presence of DSA before transplant (HR 1.69, 95%CI:
1.2-12.6; P=0.002). 
Sixty-five of the patients without pre-transplant DSA
failed to engraft. Fourteen patients received a second allo-
geneic stem cell transplantation, 24 had autologous recon-
stitution and 27 did not receive any subsequent treatment
(26 of whom died in a median time of 53 days).
The CI of Day 180-platelet engraftment was 62%. Only
3 out of 14 patients with DSA had platelet recovery (21%).
In the patients without DSA (n=280), the CI of platelet
engraftment was 73%. 
Impact of level of mean fluorescence intensity for DSA
positive patients on engraftment
Of the 14 patients with DSA, the median level of MFI
was 3900. The intensity of DSA measured by MFI was
associated with graft failure. 
All the 6 patients with DSA who engrafted had MFI
lower than median. The median MFI among the DSA
patients who experienced graft failure was 7750 (range
2032-19969), and it was 2474 (range 1226-3650) in the DSA
patients who achieved engraftment (P=0.004) (Table 2).
Of the 14 patients with DSA, 7 were transplanted with
an sUCB, and 2 of these engrafted. The level of the MFI in
these cases with engraftment was under 2500. On the
other hand, with the exception of one case, all patients
who presented graft failure had a high level of DSA (MFI
4110-22120). Of the 7 patients with DSA and transplanted
with dUCB, 3 engrafted with a unit that had an interme-
diate level of DSA (MFIs 2100, 3650 and 2500). In the
remaining 4 cases, one engrafted with the unit without
DSAs (MFIs against the non-engrafting unit were 3685),
and 3 did not engraft. In these last 3 cases, there was at
least one unit with a high level of DSA (MFI 8500, 9000,
and 7000).
Graft-versus-host disease and relapse
CI of grade II-IV acute GvHD and 3-year chronic GvHD
was 31±4% and 22±3%. The CI of aGvHD was 21% in
patients with DSA; however, the number of DSA patients
at risk was very small, as 7 out of 14 patients with DSA
died within 100 days of rejection or early relapse. No dis-
ease- or transplant-related factors were associated with
occurrence of aGvHD (such as patient and donor gender
mismatch, patient age, prior autologous transplant, type of
graft, TNC dose at collection and infusion, number of
HLA disparities, use of ATG before Day 0 and presence of
non-donor-specific anti-HLA Ab).
For the 244 patients transplanted for malignant disease
the CI of relapse at three years was 34±4%. Four out of 11
patients with malignant disease and DSA (36%) relapsed
after UCBT. 
Transplant-related mortality and overall survival
CI of TRM at one year was 36±4%. Overall, 170
patients died, and the causes of death included relapse
(n=55), GvHD (n=38), infection (n=33), rejection (n=11),
multi-organ failure (n=16), toxicity (n=9), and other causes
not specified (n=8). No significant difference was found in
the CI of TRM for patients with HLA-Ab not specific to
antigens present in the UCB units, no-DSA (n=48), when
compared with the DSA group (n=14) and with the anti-
Anti-HLA before UCBT 
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Figure 1. The cumulative incidence of engraftment at 60 days by
DSA.  The solid line represents no DSA and the dashed line repre-
sents the DSA.
Figure 2. Probability of 3-year overall survival by DSA. The solid line
represents no DSA and the dashed line represents the DSA.
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bodies negative group (n=232). CI of TRM was 32% in
case of absence of antibody and 36% for the no-DSA
group (P=0.48). The CI of TRM was 46%±8 in patients
with DSA and 32%±4 in those without antibodies
(P=0.06). Graft failure as time-dependent variable was
associated with higher risk of TRM (P=0.002) and lower
OS (P=0.002).
The probability of overall survival at three years was
42+3% with a median follow up of 36 months. The pres-
ence of DSA was associated with lower survival (42% vs.
29%; P=0.07). Also, patients transplanted with well
matched UCB (6/6 or 5/6) had a 3-year probability of sur-
vival of 50% compared to 36% (P=0.02) for those receiv-
ing UCB with 2 or more HLA mismatches. Survival was
better for patients receiving UCB graft with TNC over
3.6×107/Kg (47% vs. 36%; P=0.04). 
Discussion
In this retrospective study, we have found that the pres-
ence of donor specific HLA antibodies is an important fac-
tor for engraftment and, consequently, mortality after
reduced intensity single or double UCBT. The impact of
DSA on outcomes after transplantation has been exten-
sively described in solid organ transplantation20 in which
HLA matching is not as important as in hematopoietic
stem cell transplantation (HSCT). The effect of DSA has
also been to some extent described in the HSCT literature,
but with the advent of alternative HSCT donor this issue
has been revisited. In the context of unrelated adult HSCT,
Spellman et al.13 reported the results of a case control study
showing higher GF rate when pre-transplant DSA were
detected in the recipients of 10/10 HLA matched unrelated
donors. Therefore, presence of DSA against HLA-DP was
associated with more than 60% of the risk of GF. Recently,
in the haploidentical transplantation setting21 and in HLA
mismatched UCBT,15,16,22,23 the presence of DSA has also
been described as a factor increasing graft failure. In our
study, including 294 patients with a median follow up of
three years, we showed that the presence of DSA before
UCBT is associated with delayed engraftment and GF.
This finding translated in a trend of increased TRM and
decreased survival.  
The effect of antibodies on engraftment was only
detected when the specificity corresponded to the donor
antigen. We did not find any difference in the engraftment
rate for patients who had antibodies against an HLA not
A. Ruggeri et al.
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Table 2. Patients with DSA positivity against UCB units and their outcome.
HLA match UCB DSA DSA MFI TNC/Kg Chimerism Engraftment Other Treatment Follow up
units specificity (107) (Days) outcome (months)
1 4/6 (DRB1) 1 Class II DRB1*13:01 2490 3.3 NT No 2nd UCBT Dead-Rejection 3
DQB1*03:01 4110
DQB1*06:03 4189 
DPB1*03:01 1723
DPB1*04:02 3422
2 4/6 (A, DRB1) 1 Class I+II A*03, 11076 3 NT No Auto HSCT Dead-Rejection 1
B*51, 6672 
DP*04:01 5000
3 5/6 (B)   1 Class I B*44:03 1226 5.1 100% UCB Day 17 Alive 13
4 5/6 (A) 1 Class I+II C*01:02, 1620, 3.2 100% UCB Day 18 Dead-Infection 3
C*05:01, 1115,
DPB1*02:01 2449
5 4/6 (A, B) 1 Class I A*26  2032 4.3 Autologous  No Dead-Relapse 8
6 4/6 (A, B) 1 Class I+II B*51, 12695 4 Autologous  No Alive 59
DPB1*04:02 19969
DPB1*03:01 22120
7 4/6 (B,DRB1) 1 Class I B*07  6500 4.5 Autologous  No Dead-Relapse 3
8 4/6 (A, B) 1 Class I A*02 3000 1.5 NT No 2nd UCBT Alive 56
4/6 (A, B) 2 Class I B*44 8500 1
9 4/6 (A, B) 1 Class I A*24, 9000
5/6 (B) 2 Class I B*35 9000 2.7
B*37 3800 2.5 NT No Dead-Relapse 2
10 4/6 (A, B) 1 Class I B*44 2100 2.32 100% UCB1 Day 15 Alive 23
4/6 (A, B) 2 none NA 1.44
11 5/6 (B) 1 Class II none NA 2.24 100% UCB1 Day 8 Dead-Relapse 3
5/6 (DRB1) 2 DP*01:01 3587 1.38
12 4/6 (B, DRB1) 1 Class II DRB1*15:01  3650 1.5 100% UCB1 Day 24 Dead-GvHD 5
5/6 (B) 2 none NA 1.6
13 4/6 (A, B) 1 Class I B*57  2500 2 87% UCB1 Day 17 Dead-Infection 7
4/6 (A, B) 2 none NA 1.4
14 4/6 (A, B) 1 Class I none NA 2 Autologous  No Dead-Rejection 1
4/6 (A, B) 2 A*01 7000 2.7
HLA: human leukocyte antigen; UCB: unrelated cord blood; NT: not tested; DSA: donor specific anti-HLA antibodies; MFI: mean fluorescence intensity; TNC: total nucleated cell.
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present on the UCB. Takanashi et al.22 also reported an
increased risk of graft rejection after single UCBT and
MAC, with 38% probability of engraftment in patients
with DSA (n=20). In the setting of dUCBT, two reports
showed controversial results. The Dana Farber group15
reported the impact of DSA (n=18) on engraftment in 73
dUCBT recipients, and the effect on mortality was found
only in the group with DSA directed against both cord
blood units (n=7). However, Brunstein et al.16 showed no
association between the presence of DSA and transplant
outcomes in a series of 126 dUCBT recipients after MAC
or RIC (n=18 DSA+) in which the threshold for the detec-
tion of DSA was 500 MFI, lower than in our study.
Importantly, similar to the results showed by Cutler et al.,
in our series, a higher MFI level was associated with an
increase in GF, providing further evidence that the use of
UCB corresponding to a DSA with a high MFI level in the
recipient should be avoided. The impact of DSA with low
or intermediate level of MFI seems less clear and further
studies with larger series of patients are required to deter-
mine the optimal recipient’s MFI cut-off value for UCB
selection. In our study, all but one patient with DSA and
MFI lower than the median, engrafted. However, we
could not draw a definitive conclusion on the cut-off level
of MFI based on the small series sample.
Other HLA-related immunological factors, such as HLA-
A/B high resolution typing, HLA-C matching,10 the HLA
vector direction24 may play a role in graft failure and other
outcomes. Recently, we and others reported a lower TRM
and better survival after UCBT when selecting a non-
inherited maternal antigen (NIMA)-matched UCB unit.25,26
It is important to highlight that the use of cord blood
transplants for patients with non-malignant disorders,
such as bone marrow failure syndromes (BMFS)27 or
hemoglobinopathies and the use of RIC regimens are
known factors associated with low engraftment rate. In
our study, 14% of the population was transplanted for
BMFS, but in the multivariate analysis adjusted for the
type of diagnosis, the effect of DSA was independently
associated with graft failure (P=0.002). Another important
factor, which may have an impact on transplant results, is
the T-cell depletion using ATG before Day 0. In the mis-
matched donor setting, ATG was often given to facilitate
engraftment. More recently, conditioning regimens with-
out ATG are more frequently used, especially in the dou-
ble UCBT setting. In our series of patients, ATG use was
reported in 35% of the population. Interestingly, 4 of the
14 patients with DSA received ATG as part of condition-
ing regimen and 3 of them engrafted. It is interesting to
note that the frequency of DSA in the transplant popula-
tion varies in different publications. This may be because
of the different distribution of gender, age, parity status
and specific clinical practices. In the studies mentioned
above,15,16,22 the DSA frequencies range from 0.5% in the
Japanese group to around 20% in the American reports. In
France, the screening for donor anti-HLA antibodies has
been performed by several transplant centers since 2009;
therefore, the physicians selecting the donor may have
been aware of the presence of DSA, and, consequently,
may have preferred to select a different unit. This could
have accounted for the relatively low incidence of DSA
reported in our series (0.5%). Moreover, in our series, 12
of 14 patients with DSA were transplanted before 2009,
showing the importance of including these criteria before
selecting the UCB unit. 
Another probable explanation for the low frequency of
alloimmunization in our series is the routine use in France
since the 1980s of leukocyte reduced cellular blood com-
ponents (platelets and red cells).28
Strategies such as plasma or B-cell depletion to mini-
mize the detrimental effect of DSA on transplant out-
comes might be considered. However, the benefit of long-
lasting immune depletion should be carefully considered
in the cord blood transplant setting, and, more important-
ly, to avoid choosing a unit when the patient has DSA
against the CB unit whenever possible. Given our results,
with the objective of improving final outcomes of UCBT,
we recommend that the recipient screening and the iden-
tification of specific anti-HLA Ab should be considered
and performed using standardized methodology as soon
as the patient has an indication for an UCBT, as part of
donor selection strategy. DSA search is an effective tool to
be included in the algorithm for the best UCB unit selec-
tion. 
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